1000/1000
Hot
Most Recent
The cornelian cherry is a plant that annually provides fruits, drupe-type, ranging in color from yellow through pink, red, carmine, and almost black. Cornelian cherry bears abundant fruit in temperate climate conditions, which means that its dark-colored fruits can be treated as an excellent source of anthocyanins. After consuming, anthocyanins have a protective function in the human body. Raw fruit extracts and their pure isolates, rich in anthocyanins, have a wide spectrum of health-promoting properties.
Health-Promoting Properties | Literature | Cells Used in the Study (Population) | Study Treatment (Intervention) | Control Treatment (Comparison) | Main Findings (Outcome) |
---|---|---|---|---|---|
Anti-inflammatory activity | [25] | Ram seminal vesicles | Anthocyanins of C. mas—juice: delphinidin 3-O-‚-galactopyranoside 280 ppm, cyanidin 3-O-‚galactopyranoside 1079 ppm, and pelargonidin 3-O-‚-galactopyranoside 710 ppm | Ibuprofen, naproxen, | Ibuprofen and naproxen showed 47.5 and 54.3% of COX-I and 39.8 and 41.3% of COX-II inhibitory activities, respectively, at 10 μM concentrations. Anthocyanins 1, 2, and 3 displayed 9.2, 7.6, and 5.3% COX-I and 11.7, 12.4, and 7.8% COX-II activities, respectively. |
Anticancer activity | [26] | Lung non-small cell cancer; breast adenocarcinoma cell; ovarian cancer cell; prostate adenocarcinoma cell | Hydro-alcoholic extract of C. mas: 0, 5, 20, 100, 250, 500, 1000 μg/mL | Negative control (cells in RPMI-1640 medium) | The mean growth inhibition was 81.8%, 81.9%, 81.6%, and 79.3% in ovarian cancer, breast adenocarcinoma, prostate adenocarcinoma, and lung non-small cell cancer, respectively. |
[27] | Breast adenocarcinoma, cervix epithelioid carcinoma, lung adenocarcinoma | containing different amounts of anthocyanins depending on growth locations CC1 0.89, CC2 0.80, CC3 1.40, CC4 1.08 mg CyGE·g−1 FW | Negative control (Cells in DMEM medium) (PAA Laboratories GmbH, Pashing, Austria) | The antiproliferative activity of cornelian cherry fruit extracts depended on growth locations. Wild cornelian cherry (CC3) from Drinić had the highest monomeric anthocyanin content and the highest inhibition of free radicals (IC50DPPH = 262.19 mg/mL; IC50ABTS = 76.78 mg/mL; IC50OH˙ = 102.31 mg/mL) and inhibition of breast adenocarcinoma cell line growth (IC50MCF-7 = 1.37 mg/mL). | |
Antihyperglycemic effects | [28] | Rodent pancreatic β-cells (INS-1 832/13) | Purified delphinidin-3-glucoside from C. officinalis fruits. cyanidin-3-galactoside and pelargonidin-3-galactoside from C. mas fruits: 5, 10, 50, 100 and 250 μg·mL−1. | Negative control (cells in RPMI-1640 medium) | Delphinidin 3-O-glucoside, cyanidin 3-O-galactoside, and pelargonidin 3-O-galactoside were distinguished as the most effective anthocyanins to stimulate insulin secretion. |
Antihyperlipidemic effects | [29] | Porcine pancreas powder | Water and ethanolic extract of C. mas and C. alba; pelargonidin 3-O-galactoside: 7.5 μg·mL−1 | Negative control (Porcine pancreas powder in Tris-HCl buffer, pH 8.0) | The most active anthocyanin in the inhibition of pancreatic lipase activity was pelargonidin 3-O-galactoside. |
Effects | Literature | Animals Subjected to Tests (Population) | Study Treatment (Intervention) |
Control Treatment (Comparator) |
Main Findings (Outcome) |
---|---|---|---|---|---|
Antioxidant activity | [30] | 8–12 weeks male NMRI mice treated with Methotrexate (MTX) | CMFE (250, 500, 1000 mg·kg−1) and Vitamin E (100 IU kg−1) | physiologic saline | Both Vit E and CMFE were able to protect from MTX-induced effects on sperm maturity and DNA damage. |
Protective effect on the heart | [31] | Rats treated with carbon tetrachloride (CCl4) | Pre and post-treatment CMFE 300 and 700 mg·kg−1 | Control group without CMFE | CMFE significantly decreased the increased levels of serum lactate dehydrogenase, serum creatine kinase, and myocardial lipid peroxides and significantly increased the myocardial endogenous antioxidants (glutathione peroxidase, superoxide dismutase, and catalase) levels. |
Protective effect on the liver | [32] | Wistar strain male albino rats treated with carbon tetrachloride | CMFE 200 and 500 mg·kg−1 and Silymarin 100 mg·kg−1 | irrigated with drinking water | Oral administration of CMFE provided significant liver protection by reducing elevated serum enzyme levels, total serum protein, albumin, and hepatic lipid peroxidation content. |
[33] | Wistar strain male albino rats treated with carbon tetrachloride | CMFE 200 and 500 mg·kg−1 per 16 days and CMFE 200 and 500 mg·kg−1 administered 2, 6, 12, 24 and 48 h after CCl4 toxication | irrigated with drinking water | The activities of antioxidant enzymes (MDA, CAT, SOD, GPx) in the CCl4-treated group were lower than those in the normal control. The activity of these enzymes in the CMFE-treated groups increased significantly compared to the toxic group. | |
[34] | Wistar strain male albino rats treated with methotrexate (MTX) | CMFE 700 mg·kg−1 per 7 days and Mice first day treated with MTX and then treated with 300, 700, and 1400 mg for 7 days | physiologic saline | Rats treated with MTX were characterized by significantly higher total bilirubin values and higher AST, ALT, and ALB values compared to rats treated with CMFE. The most beneficial effect on the normalization of the above-mentioned parameters after MTX administration was CMFE treatment at a dose of 1400 mg·kg−1. | |
Protective effect on the kidneys | [35] | Wistar strain male albino rats treated with carbon tetrachloride- | Prophylactic groups: CMFE 300 and 700 mg·kg−1, for 16 days, respectively and on the 16th day received CCl4 and curative groups: distilled water orally for 16 days and on the 16th day they received CCl4 (1 mL·kg−1 b.w.; 80% in olive oil), followed by CMFE 300 mg·kg−1 and 700 mg·kg−1, respectively, at 2, 6, 12, 24 and 48 h after CCl4 intoxication | “Sham” control for both preventive and therapeutic studies, receiving raw water and free access to food for 16 days and control for both preventive and therapeutic studies, receiving distilled water orally for 16 days, and on day 16 received olive oil daily (1 mL kg−1 b.w.) | Different doses of fruit extract (300 and 700 mg/kg−1) significantly ameliorated the alterations induced by CCl4 in lipid peroxidation, antioxidant defenses, and biochemical and renal lesions. The level of antioxidant enzymes such as SOD, CAT, and GPx decreased in the CCl4-treated group and improved by treatment with CMFE. |
Protective effect on the brain | [36] | 12-week Wistar strain male albino rats | Rats with fructose diet (with CMFE) | Rats with a diet enriched in fat | Addition of CMFE stimulates PON activity, both in brain tissue and in plasma, and increases the protection of the nervous system from oxidative stress by increasing the activity of CAT. Protects proteins against peroxidation, as can be shown by the level of PCG. |
[37] | Wistar rats with streptozotocin-induced Alzheimer’s Disease | Flavonoid from CMFE at 5, 10 and 20 mg·kg−1 | saline-saline control, streptozotocine-saline control | CMFE treatment increased memory retention in a dose-dependent manner. The dose of 10 mg kg–1 decreased rat weight significantly. | |
Protective effect on bones | [38] | Zucker diabetic fatty (ZDF) rats | diabetic obese rats receiving 500 and 1000 mg·kg−1 b.w. of CMFE |
non-diabetic lean rats | A higher dose of CMFE had a beneficial impact on femoral weight, cortical bone thickness, relative volume of trabecular bone, and trabecular thickness. |
[39] | 12-week-old female Wistar Rats with ovariectomy-induced metabolic changes |
ovariectomized animals receiving 17β-oestradiol; group with CMFE (50 mg·kg−1) |
“Sham” operated group and ovariectomized control group | CMFE ameliorated ovariectomy-induced decrease in femoral and tibial bone mineral density (BMD), prevented the deterioration in Young’s modulus and flexural strength and counteracted ovariectomy-induced decrease in serum calcium level. |
|
Antihyperglycemic | [40] | Adult male rats with alloxan-induced diabetes | glibenclamide-treated (0.6 mg·kg−1·day−1; 4 weeks) and CMFE-treated (2 g−1 day; 4 weeks) group | non-diabetic control and diabetic control | Diabetic rats had significantly elevated levels of serum glucose, LDL-C, TG, AST, ALP, and ALT and decreased levels of HDL-C compared to the non-diabetic group. The effects of CMFE were comparable to those of glibenclamide at the doses tested in this study. |
[41] | Zucker diabetic fatty (ZDF) rats | CMFE in two doses (500 and 1000 mg·kg−1 b.w., 10 weeks) | non-diabetic lean controls received only distilled water | significant decrease of glucose level after oral administration of CMFE in a dose of 1000 mg/kg bw in the pre-diabetic state of animals (until the 7th week of the experiment) and significant restriction of water intake in both CMFE groups against the diabetic control. | |
[5] | Male Wistar rats with streptozotocin-induced diabetes mellitus | CMFE extracts (20 mg kg−1 of b.w., 14 days) | control group (healthy) | CMFE lowered blood glucose and improved glucose tolerance. Significantly decreased the amount of glycated hemoglobin (by 25%) and increased erythrocyte resistance to acid hemolysis. | |
Antihyperlipidemic effects | [42] | C57BL/6 mice fed a high-fat diet | mice were fed with a high-fat diet plus anthocyanins (1 g·kg−1) or ursolic acid 500 mg·kg−1) | mice were fed a normal diet | The anthocyanin showed a 24% decrease in weight gain and decreased lipid accumulation in the liver, including a significant decrease in liver triacylglycerol concentration. Anthocyanin and ursolic acid have extremely elevated insulin levels. |
[40] | Adult male rats with alloxan-induced diabetes mellitus | glibenclamide-treated (0.6 mg/kg/day; 4 weeks) and CMFE (2 g·day−1; 4 weeks) group | non-diabetic control and diabetic control, | Treatment with glibenclamide or CM counterbalanced significantly increased serum glucose, LDL-C, TG, AST, ALP, and ALT levels and decreased HDL-C levels in diabetic rats. | |
[43][44][45] | Adult male New Zealand rabbits with high cholesterol (1%) diet-induced hyperlipidemia | CMFE (100 mg·kg−1 b.w., 60 days) or simvastatin (5 mg·kg−1 b.w., 60 days) or loganic acid (20 mg·kg−1 b.w.) | control group with a standard diet and group with hyperlipidemia | CMFE led to a 44% significant decrease in serum TG levels and prevented the development of atheromatous changes in the thoracic aorta. CMFE significantly increased PPARα, had a significant protective effect on diet-induced oxidative stress in the liver, as well as restored upregulated pro-inflammatory cytokines serum levels. | |
[46] | Adult male New Zealand rabbits with high cholesterol (1%) diet-induced hyperlipidemia | CMFE (10 or 50 mg·kg−1 b.w.) or simvastatin (5 mg·kg−1 b.w.) | control group with a standard diet for rabbits and a group with hyperlipidemia | CMFE enhancement in PPAR-α and PPAR-γ expression in the aorta, LXR-α expression in the liver, a decrease in TG, leptin, and resistin, and an increase in adiponectin levels. | |
[47] | Adult male New Zealand rabbits with high cholesterol (1%) diet-induced hyperlipidemia | Group with a standard diet containing C. mas powder (1 g·kg−1 b.w.) diet, and with a high cholesterol (1%) containing C. mas powder (1 g·kg−1) diet, and a high cholesterol containing lovastatin (10 mg·kg−1 b.w.) diet | control group with a standard diet for rabbits and with a high cholesterol (1%) diet | C. mas powder and lovastatin significantly decreased fibrinogen levels in comparison with the high cholesterol group. Furthermore, C mas. powder could reduce the fibrinogen level more than lovastatin | |
[48] | Healthy male Wistar rats | CMFE (50, 200 and 400 mg·kg−1 b.w., 3 weeks) | Normal control with normal diet without any injection and placebo control and intraperitoneally received a normal saline | All doses of CMFE significantly decreased HDW and PDW vs. the control group. Only high doses caused a significant elevation in MCHC, MPV, and PCT and a significant decrease in RDW vs. the control group. | |
Protective effect on the eyes | [49] | Sexually mature, New Zealand white rabbits, aged between 6 and 12 months, were used: 7 males and 7 females | Intraconjunctival administration of one drop loganic acid or polyphenolic fraction of C. mas, corresponding to a volume of 50 µL, to the right eye | One drop of artificial tears containing 0.15% sodium hyaluronate (50 µL) was administered to the left eye as a placebo | Loganic acid (50%) and pelargonidin-3-galactoside (7%) were found as the main components of C. mas fraction. Therefore, the hypotensive effect was attributed to loganic acid. |
Effects | Literature | Type of Patients (Population) | Dose of Cornelian Cherry Extract and Period of Its Intake (Intervention) | Control Treatment (Comparator) | Main Findings (Outcome) |
---|---|---|---|---|---|
Protective effect on the liver | [50] | Patients with non-alcoholic fatty liver disease (NAFLD) | CMFE (320 mg·d−1 anthocyanins; 12 weeks). | Control group received the placebo, matched with the extract in terms of appearance, taste, color, and texture (but without any anthocyanins) for 12 weeks | Results indicated that anthocyanins had some impacts on NAFLD. |
[51] | Patients with non-alcoholic fatty liver disease (NAFLD) | CMFE (320 mg·d−1 anthocyanins; 12 weeks). | Control group received the placebo, matched with the extract in terms of appearance, taste, color, and texture (but without any anthocyanins) for 12 weeks | No significant impact of CMFE on serum ALT and AST levels, as well as hepatic steatosis among NAFLD patients. A significant reduction was observed in the levels of CK-18 among the CMFE group at the end of the study. No significant difference was found between the CMFE and placebo groups with regard to this marker. Fibrosis score increased significantly in the placebo group at the end of the study. | |
Antihyperglycemic | [52] | Patients with type 2 diabetes mellitus | 300 mg d−1 anthocyanins; 6 weeks | Placebo capsules; 6 weeks | Significant increase in insulin levels and a decrease in HgbA1 C and TG levels was observed in the drug group compared to the placebo. |
Antihyperlipidemic effects | [53] | Dyslipidemic children and adolescents | 50 g of CMFE twice a day after lunch and dinner, 6 weeks | Diet without CMFE, 6 weeks | After week 6 of the trial, the TC, TG, LDL-C, apo B, ICAM-1, and VCAM-1 levels in the CMFE group were significantly lower, and the HDL-C and apo A-I levels were higher than at baseline. |
[54] | Patients with non-alcoholic fatty liver disease (NAFLD) | 20 cc/d CMFE, 12 weeks | Placebo, 12 weeks | Treatment group, compared to the control group, showed a significant reduction in DBP and SBP. No difference between groups in weight, WC, HC, WHR, BFM, BFP, and FFM. Significant reduction in the treatment group compared to the control group in BFM and BFP. | |
Protective effect on the urinary system | [55] | Women with chronic cystitis (UTIs) | C. mas tablet 500 mg·day−1, 6 month | Placebo, 12 weeks | C. mas decreases dysuria among patients with UTIs. |